Learning From Three Filler Occlusion Cases

A 2024 report from China describes three young women who developed blood-vessel blockages after hyaluronic acid filler in the forehead, frown area and nose. The two who stayed in treatment recovered well, while the one who left early returned days later with skin damage and was left with scarring. The lesson for patients is simple: recognize warning signs early and stay in close contact with your treating clinic until the problem has fully settled.

Why this was published

Vascular occlusion, where filler blocks or squeezes a blood vessel, is uncommon but is one of the complications injectors train hardest to prevent and treat. Individual case reports remain an important way the field shares experience, because these events are too rare and too urgent to study in large controlled trials. This paper pairs three cases with an overview of prevention and treatment.

What happened in the three cases

Forehead. A 30-year-old woman had immediate pain, redness and swelling, then a blotchy discolouration of her forehead. Later that day she developed blurred and double vision. She reached the treating team within about an hour of symptoms starting and received repeated hyaluronidase, the enzyme that dissolves hyaluronic acid filler, along with other supportive treatment. Her skin healed, and her vision was reported as normal at follow-up.

Frown area. A 26-year-old woman had sudden loss of vision in one eye with eye pain, nausea and a drooping eyelid after a glabellar injection. She also arrived within an hour and received the same approach. At one month, her vision and skin were reported to have returned to normal.

Nose. A 24-year-old woman developed pain and a bluish-purple colour over her nose and upper lip. She received hyaluronidase at her first visit but chose to leave the hospital. Three days later she came back with pus-filled spots on her nose and dead skin between her eyebrows. At follow-up she had scarring in both areas.

A note on the eye cases

Recovery of vision after a filler-related eye artery blockage is not typical. Many published reports describe lasting vision loss even with fast treatment. These two outcomes are encouraging but should not be taken to mean vision loss is usually reversible. The report itself contains some inconsistencies in follow-up times and dosing details, which is another reason to read individual outcomes cautiously.

What the authors recommend

For prevention, the authors describe five things an injector should assess before treatment: your general health and history (including previous surgery, injections and allergies), what you hope to achieve (to avoid overfilling and high-risk vessels), the condition of your skin, your sensitivity to pain, and a clear explanation of risks so that you know to report symptoms early.

For treatment, they emphasize prompt and repeated hyaluronidase, with additional measures to improve blood flow, prevent infection and support healing. For eye involvement, they describe specialist eye treatment. Approaches to the supporting medicines vary between published guidelines, which is discussed in our article on the published guideline for managing vascular occlusion.

Some of the specific medicines and doses mentioned in the paper reflect local practice and may not be used in Canada. That does not change the broad message, which is consistent across most published advice: dissolve hyaluronic acid filler early and repeatedly when needed, support healing, and refer quickly to an eye specialist when vision is affected.

How strong is this evidence?

Three case reports cannot tell us how often occlusion happens, which treatments work best, or how likely recovery is. The authors acknowledge this. Case reports are best read as illustrations: they show what can happen, how it looked, and what one team did. They are useful for teaching recognition and response, not for predicting your own risk.

What it means for you

The most practical lesson comes from the third case. Even after the first dose of enzyme, a blockage may need repeated treatment and close monitoring over several days. Leaving care early can allow damage to progress. If your injector asks you to return or stay for observation, it is for good reason.

Contact your clinic right away, day or night, if you notice any of these during or after filler:

• pain that is severe, worsening or feels out of proportion;
• skin that becomes pale, dusky, blue, purple or mottled;
• blisters, pimple-like spots or dark scabs appearing over the following days;
• any change in vision, eye pain, a drooping eyelid, nausea with headache, or weakness, which needs emergency care immediately.

Physician-led clinics keep hyaluronidase and emergency protocols ready, and should give you clear after-care instructions and a way to reach them. Our article on vascular occlusion safety explains how risk is reduced, and filler swelling and bruising covers what normal healing looks like.

Questions to ask at your consultation

• Which areas you are treating carry higher risk, and how do you reduce it?
• How would I reach you if I had symptoms after hours?
• Will you check my skin before I leave, and when should I follow up?

At HealthPark, these points are part of the consent discussion before filler, so you know exactly what to watch for.

Frequently asked questions

How quickly do symptoms appear?

Most blood-flow problems show up during the injection or within hours, but some signs, such as blistering or dark patches, can become more obvious over the next few days.

Is the nose a high-risk area?

Yes. The nose, frown area and forehead are widely considered higher-risk areas for filler because of their blood supply and connections to the eye's arteries.

If the enzyme works, am I fine?

Often, but not always after one dose. Repeated treatment and follow-up checks are common until blood flow is clearly restored and the skin has healed.

If you are considering filler and want to understand the risks in a calm, practical way, a consultation is a good place to start.

Source

Wang R, Li Y, Li Z, Yao H, Zhai Z. Hyaluronic acid filler-induced vascular occlusion: three case reports and overview of prevention and treatment. Journal of Cosmetic Dermatology, 2024. Read the study